Abstract
Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors after conventional treatment. The advent of selective cell culture protocols for the propagation of patient-derived glioma stem-like cells (GSCs) provides researchers the ability to selectively study the cells that could be at the root of tumor proliferation and resistance to therapy. As these techniques are widely applied in contemporary studies and becoming the preferred in vitro model, molecular characterization of GSCs is considered pivotal for the identification and advancement of novel therapies for this devastating disease.
This review aims to provide an overview of canonical molecular alterations defining subtypes of malignant glioma as derived from genotypic, transcriptomic and epigenetic profiling in relation to their representation in GSC models. The distribution of these hallmark alterations as found in characterization studies of GSCs is compared between publications. Finally, conclusions of these studies with respect to coverage of driving alterations and translational relevance are provided. By doing so, we provide a contemporary overview of scientific results derived from GSC models and hopefully create appreciation of the advantages and caveats of utilizing these models for studying malignant glioma.Keywords: Glioblastoma, in vitro models, GSC, tumor profiling, TCGA, cell culture, tumor heterogeneity.
Current Cancer Drug Targets
Title:Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Volume: 17 Issue: 3
Author(s): Rutger K. Balvers, Clemens M.F. Dirven, Sieger Leenstra and Martine L.M. Lamfers
Affiliation:
Keywords: Glioblastoma, in vitro models, GSC, tumor profiling, TCGA, cell culture, tumor heterogeneity.
Abstract: Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors after conventional treatment. The advent of selective cell culture protocols for the propagation of patient-derived glioma stem-like cells (GSCs) provides researchers the ability to selectively study the cells that could be at the root of tumor proliferation and resistance to therapy. As these techniques are widely applied in contemporary studies and becoming the preferred in vitro model, molecular characterization of GSCs is considered pivotal for the identification and advancement of novel therapies for this devastating disease.
This review aims to provide an overview of canonical molecular alterations defining subtypes of malignant glioma as derived from genotypic, transcriptomic and epigenetic profiling in relation to their representation in GSC models. The distribution of these hallmark alterations as found in characterization studies of GSCs is compared between publications. Finally, conclusions of these studies with respect to coverage of driving alterations and translational relevance are provided. By doing so, we provide a contemporary overview of scientific results derived from GSC models and hopefully create appreciation of the advantages and caveats of utilizing these models for studying malignant glioma.Export Options
About this article
Cite this article as:
Balvers K. Rutger, Dirven M.F. Clemens, Leenstra Sieger and Lamfers L.M. Martine, Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666160813191809
DOI https://dx.doi.org/10.2174/1568009616666160813191809 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Bioactive Polysaccharides From Natural Resources For Cancer Therapy
Bioactive polysaccharides from natural resources exhibit diverse therapeutic properties including anticancer, antioxidant, antidiabetic, immunostimulatory activity, and promotion of wound healing. In the past decades, most studies focused on the extraction and identification of polysaccharides, as well as their biological activities. A large number of bioactive polysaccharides with different structural features ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Innovative Drug Research Propelling a New Era of Precision Oncology
Drug-oncology research is leading a new era of precision medicine, becoming a frontier hotspot in cancer treatment. Advancements in molecular biology, genomics, and medicinal chemistry have driven revolutionary changes in cancer cognition and treatment strategies. Gene-targeted drugs provide more precise treatments, improving survival rates for certain cancers. Network pharmacology offers ...read more
Novel Targets in Cancer Immunotherapy
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has greatly revolutionized therapeutic strategies in the field of cancer. Current targets of FDA-approved ICIs include CTLA-4, PD-1/PDl-1, and LAG-3. However, the prognosis of cancer patients, especially with solid tumors, remains unfavorable due to the intrinsic and acquired resistance. For the past decades, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
WDFY3-AS2: A Potential Prognostic Factor and Therapeutic Target
Related to Cancer
Current Medicinal Chemistry Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design Targeting the JAK/STAT Signaling Pathway for Breast Cancer
Current Medicinal Chemistry Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Biological Potential of a Bibenzyl Compound ‘Gigantol’ for the Treatment of Human Disorders: Pharmacological Activities and Analytical Aspects of an Active Phytochemical Isolated from Orchid
Current Drug Therapy Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Brainstorming the New Avenues for Translational Proteomics Research: First Indo-US Bilateral Proteomics Workshop
Current Proteomics Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research A Comprehensive Insight Towards Pharmaceutical Aspects of Graphene Nanosheets
Current Pharmaceutical Biotechnology FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Herbal Based Polymeric Nanoparticles as a Therapeutic Remedy for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery